Cargando…
Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
Type I interferon (IFN) has been approved as an anticancer agent to treat some malignancies. However, IFNs have a short in vivo half-life, systemic toxicity, and poor biophysical properties, which prevent it from being widely used for cancer therapy. This study aimed to construct recombinant IFN-β-1...
Autores principales: | Lee, Chan Gyu, Kim, TaeEun, Hong, Sungyoul, Chu, Jongwan, Kang, Ju Eun, Park, Hee Geon, Choi, Jun Young, Song, Kyoung, Rha, Sun Young, Lee, Soohyeon, Choi, Joon-Seok, Kim, Sun Min, Jeong, Hae Min, Shin, Young Kee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832035/ https://www.ncbi.nlm.nih.gov/pubmed/33505314 http://dx.doi.org/10.3389/fphar.2020.608774 |
Ejemplares similares
-
A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics
por: Lee, Saehyung, et al.
Publicado: (2019) -
MuteinDB: the mutein database linking substrates, products and enzymatic reactions directly with genetic variants of enzymes
por: Braun, Andreas, et al.
Publicado: (2012) -
Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
por: Roh, Jong-Lyel, et al.
Publicado: (2014) -
The antitumor effect induced by an IL-2 ‘no-alpha’ mutein depends on changes in the CD8(+) T lymphocyte/Treg cell balance
por: Carmenate, Tania, et al.
Publicado: (2022) -
Development of Human Monoclonal Antibody for Claudin-3 Overexpressing Carcinoma Targeting
por: Yang, Hobin, et al.
Publicado: (2019)